Terug

PLCRC-QUALITAS: QUAlity of LIfe in meTAStatic colorectal cancer patients treated with trifluridine-tipiracil in late line in the PLCRC cohort

We started the PLCRC-QUALITAS study in early 2017. The aim of PLCRC-QUALITAS is to investigate the quality of life of patients treated with trifluridine tipiracil. Quality of life is the perceived quality of an individual’s daily life, an assessment of his well-being or lack thereof. In addition, quality of life also includes objective aspects, such as limitations that someone has as a result of his illness.

Through the aforementioned research into the effectiveness of trifluridine tipiracil, we know that patients are treated with this drug for an average of 13 weeks. The regular questionnaires on quality of life within PLCRC are sent once every 3 to 12 months. This yields too little data about the patients treated with trifluridine tipiracil. Therefore, we ask patients who participate in PLCRC and start with trifluridine tipiracil to complete a QUALITAS questionnaire each month. This can be done on paper or digitally. The regular PLCRC questionnaires are (temporarily) discontinued.

Terug